Home Featured Page 146

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of...

Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain

PT373 – Integrative Psychiatry & The Safety of At-Home Ketamine

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics...

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of...

PT372 – The Heroic Hearts Project: Veterans and The Impact of...

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Healthline – Mental Health Breakthrough: The Therapeutic Benefits of Psychedelics

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

Racing Beyond Racemic: A Look at Ketamine Drug Development Ahead of...

Surprising Results: Psilocybin Trial for Depression Alleviates Chronic Pain

PT373 – Integrative Psychiatry & The Safety of At-Home Ketamine

Interview | Elliot Marseille, Global Initiative for Psychedelic Science Economics...

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelics Weekly – Wonderland Controversy and Colorado Proposition 122

Psychedelic Bulletin #123: Colorado Psilocybin Therapy Prop Passes While Swathes of...

PT372 – The Heroic Hearts Project: Veterans and The Impact of...

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Healthline – Mental Health Breakthrough: The Therapeutic Benefits of Psychedelics

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY